Syschem (India) Limited announced the final voting results for its Thirty-Third Annual General Meeting held on September 30, 2026. All eleven resolutions proposed at the meeting were passed with the requisite majority, confirming shareholder approval for key governance and operational matters.

Directorial changes and appointments

The shareholders approved the re-appointment of Ranjan Jain as a director retiring by rotation. Additionally, special resolutions were passed to re-designate Jain as Whole Time Director and Suninder Veer Singh as Managing Director, with their remuneration packages fixed accordingly. The meeting also addressed the appointment of auditors for casual vacancies and statutory roles for a five-year term.

The scrutinizer's report detailed that the resolution to re-designate Ranjan Jain as Whole Time Director received 96.01% votes in favour, while the similar resolution for Suninder Veer Singh as Managing Director also secured 96.01% support. The re-appointment of Ranjan Jain as director retiring by rotation was approved with 99.99% votes in favour.

Related party transactions

Ordinary resolutions were passed to approve material related party transactions for the period spanning from the 33rd to the 34th Annual General Meeting. These transactions involve partnerships with Pharmacare International, Indosol Export, and JB Khokhani & Co.

For each of the three related party transaction resolutions, the voting results showed 99.10% votes in favour and 0.90% against. Notably, votes cast by the related parties themselves were considered invalid for these specific resolutions, leaving a smaller pool of eligible voters but maintaining high approval rates among non-related shareholders.

Governance and compliance

The company secretary confirmed that remote e-voting facilities were available from September 27 to September 29, 2026. Kanwaljit Singh Thanewal served as the scrutinizer for the e-voting process. The results of the voting were unblocked on September 30, 2026, in the presence of witnesses not employed by the company.

What the numbers show

The voting data reveals a distinct pattern in shareholder sentiment regarding executive compensation versus operational continuity. While routine matters like financial statement adoption and auditor appointments achieved near-unanimous support (100.00% in favour), the special resolutions for re-designating directors as Whole Time Director and Managing Director saw a noticeable dip in support to 96.01%. This indicates that approximately 3.99% of valid votes opposed or abstained from the specific remuneration and role changes for senior management, contrasting sharply with the overwhelming approval for standard governance items.

Syschem (India) Limited will hold its 33rd Annual General Meeting (AGM) on September 30, 2026. The meeting aims to approve a leadership swap between its Managing Director and Whole-Time Director, appoint new statutory auditors, and ratify significant related party transactions.

The company recently reported a dramatic turnaround in FY26, with net profit after tax surging to ₹1,092.90 lakh from ₹46.01 lakh in FY25. Revenue from operations grew by 69% to ₹65,462.60 lakh, driven by increased production capacity following the commencement of commercial operations at its new manufacturing facility.

Financial Performance

Syschem’s revenue from operations rose significantly to ₹65,462.60 lakh in FY26, compared to ₹38,623.10 lakh in FY25. This growth was accompanied by a substantial improvement in profitability:

The operating profit before working capital changes stood at ₹2,109.29 lakh, up from ₹401.82 lakh in the previous year. Cash generated from operations improved to ₹1,144.93 lakh, reversing a cash outflow of ₹954.23 lakh in FY25. The company did not declare any dividend for the financial year.

Leadership Restructuring

Shareholders are being asked to approve the re-designation of key management personnel effective September 30, 2026. Mr. Suninder Veer Singh will be promoted from Whole-Time Director to Managing Director, while Mr. Ranjan Jain will move from Managing Director to Whole-Time Director. Both directors will serve five-year terms and receive remuneration up to ₹7 lakh per month for an initial period of three years.

This proposal follows an earlier Postal Ballot where the special resolution did not receive the requisite majority of votes. The Nomination and Remuneration Committee reconsidered the proposal, citing improved operational efficiency and strategic business expansion as reasons for the realignment of roles.

Related Party Transactions

The AGM agenda includes the approval of material related party transactions for the period between the 33rd AGM and the 34th AGM. The proposed transactions include:

• Pharmacare International: Up to ₹600 crore for sales, purchases, and services.
• Indosol Export: Up to ₹100 crore for similar transactions.
• JB Khokhani & Co: Up to ₹100 crore for sales, purchases, and services.

Additionally, shareholders are requested to ratify a corporate guarantee of ₹50 crore provided to Pharmacare International for credit facilities availed from HDFC Bank. The Audit Committee has reviewed these transactions and confirmed they are conducted at arm's length.

Auditor Appointment

M/s Bansal Vijay & Associates has been appointed as the statutory auditor for a five-year term, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The proposed fee is ₹2.5 lakh per annum plus GST. M/s STAV & Co resigned citing regulatory requirements regarding its Peer Review Certificate.

What the Numbers Show

The surge in net profit is primarily operational, driven by the ramp-up of the new manufacturing plant which led to a 69% increase in revenue. While finance costs increased to ₹226.35 lakh from ₹6.60 lakh, this was largely due to exchange fluctuations (₹115.56 lakh) rather than higher debt burdens, as total borrowings remained minimal at ₹40.16 lakh. The company’s ability to convert revenue growth into significant profit expansion highlights improved operational leverage.